NervGen Pharma Corp. (NGEN) — Financial Flexibility Index

Latest as of March 2026: -0.55x

NervGen Pharma Corp. (NGEN) has a Financial Flexibility Index of -0.55x as of March 2026. Free cash flow of $-8.34 Million (operating CF $-8.34 Million minus capex $4.18) represents -1% of total liabilities ($15.21 Million). Check NGEN PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Financial Flexibility Index

-0.55x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-8.34 Million
Operating CF − Capex

Total Liabilities

$15.21 Million
USD

Capital Expenditures

$4.18
USD

NervGen Pharma Corp. Financial Flexibility Index (2018–2025)

Historical Financial Flexibility Index trend for NervGen Pharma Corp. across 8 annual periods. See NGEN working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Annual Financial Flexibility Index for NervGen Pharma Corp. (2018–2025)

Year-by-year free cash flow to debt coverage for NervGen Pharma Corp.. For the full company profile including market capitalisation, see NGEN market cap overview.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -0.99x $-19.50 Million $-19.50 Million $19.73 Million ▲ +0.8%
2024 -1.00x $-16.83 Million $-16.83 Million $16.90 Million ▼ -34.5%
2023 -0.74x $-11.29 Million $-11.30 Million $15.25 Million ▲ +56.6%
2022 -1.71x $-17.61 Million $-17.63 Million $10.32 Million ▲ +77.8%
2021 -7.67x $-8.33 Million $-8.33 Million $1.09 Million ▲ +8.2%
2020 -8.35x $-6.32 Million $-6.32 Million $756.78K ▲ +4.7%
2019 -8.76x $-8.31 Million $-8.31 Million $949.14K ▼ -391.1%
2018 -1.78x $-1.04 Million $-1.04 Million $581.26K
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities